title: Potential biological targets for anti-Alzheimer drugs.
abstract: The stunning accumulation of data on the physiopathology of Alzheimer's disease is a real hinderance to pharmacologists who have to make decisions as to what molecules should be assessed first in man. Considering the cumbersomeness and cost of clinical trials in that field, a review of potential targets for drugs that are supposed to be active against the disease has become necessary, for a true definition of the rational justifications of trials to be envisaged.
authors.affiliation: Laboratoire de Pharmacologie, Faculté de Médecine, Hôpital Pontchaillou, Rennes, France.
authors.forename: H
authors.initials: H
authors.lastname: Allain
authors.forename: S
authors.initials: S
authors.lastname: Belliard
authors.forename: J
authors.initials: J
authors.lastname: de Certaines
authors.forename: D
authors.initials: D
authors.lastname: Bentué-Ferrer
authors.forename: M
authors.initials: M
authors.lastname: Bureau
authors.forename: P
authors.initials: P
authors.lastname: Lacroix
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism; D000641:Ammonia / Q000378:metabolism; D000682:Amyloid / Q000378:metabolism / Q000502:physiology; D016923:Cell Death / Q000187:drug effects; D006801:Humans; D018377:Neurotransmitter Agents / Q000378:metabolism / Q000502:physiology
chemical_list: D000682:Amyloid; D018377:Neurotransmitter Agents; D000641:Ammonia